Ernexa Therapeutics Inc. Increase (Decrease) in Contract with Customer, Liability
Ernexa Therapeutics Inc. (ERNA) reported Increase (Decrease) in Contract with Customer, Liability of -$384.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-11.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2021-03-11
- Ernexa Therapeutics Inc. increase (decrease) in contract with customer, liability for the quarter ending 2020-12-31 was -$42.00K.
- Ernexa Therapeutics Inc. increase (decrease) in contract with customer, liability for the quarter ending 2020-09-30 was -$258.00K, a 179.38% decline year-over-year.
- Ernexa Therapeutics Inc. increase (decrease) in contract with customer, liability for the quarter ending 2020-06-30 was -$7.00K.
- Ernexa Therapeutics Inc. increase (decrease) in contract with customer, liability for the quarter ending 2020-03-31 was -$77.00K.
- Ernexa Therapeutics Inc. increase (decrease) in contract with customer, liability for fiscal 2020 was -$384.00K.
- Ernexa Therapeutics Inc. increase (decrease) in contract with customer, liability for fiscal 2019 was -$835.00K.
- Ernexa Therapeutics Inc. increase (decrease) in contract with customer, liability for fiscal 2018 was -$2.23M, a 194.81% decline from fiscal 2017.
- Ernexa Therapeutics Inc. increase (decrease) in contract with customer, liability for fiscal 2017 was $2.35M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | -$300.00K derived: sum of 2 quarters · filed 2021-03-11 | -$307.00K derived: sum of 3 quarters · filed 2021-03-11 | -$384.00K 10-K · filed 2021-03-11 |
| 2020-09-30 | -$258.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | -$265.00K derived: sum of 2 quarters · filed 2020-11-13 | -$342.00K 10-Q · filed 2020-11-13 | -$636.00K derived: sum of 4 quarters · filed 2021-03-11 |
| 2020-06-30 | -$7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$84.00K 10-Q · filed 2020-08-07 | -$378.00K derived: sum of 3 quarters · filed 2021-03-11 | -$53.00K derived: sum of 4 quarters · filed 2021-03-11 |
| 2020-03-31 | -$77.00K 10-Q · filed 2020-05-20 | -$371.00K derived: sum of 2 quarters · filed 2021-03-11 | -$46.00K derived: sum of 3 quarters · filed 2021-03-11 | -$728.00K derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-12-31 | -$294.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $31.00K derived: sum of 2 quarters · filed 2021-03-11 | -$651.00K derived: sum of 3 quarters · filed 2021-03-11 | -$835.00K 10-K · filed 2021-03-11 |
| 2019-09-30 | $325.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | -$357.00K derived: sum of 2 quarters · filed 2020-11-13 | -$541.00K 10-Q · filed 2020-11-13 | -$1.56M derived: sum of 4 quarters · filed 2020-11-13 |
| 2019-06-30 | -$682.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$866.00K 10-Q · filed 2020-08-07 | -$1.88M derived: sum of 3 quarters · filed 2020-08-07 | -$2.25M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | -$184.00K 10-Q · filed 2020-05-20 | -$1.20M derived: sum of 2 quarters · filed 2020-05-20 | -$1.56M derived: sum of 3 quarters · filed 2020-05-20 | -$2.23M derived: sum of 4 quarters · filed 2020-05-20 |
| 2018-12-31 | -$1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | -$1.38M derived: sum of 2 quarters · filed 2020-03-19 | -$2.05M derived: sum of 3 quarters · filed 2020-03-19 | -$2.23M 10-K · filed 2020-03-19 |
| 2018-09-30 | -$361.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-01 | -$1.03M derived: sum of 2 quarters · filed 2019-11-01 | -$1.21M 10-Q · filed 2019-11-01 | |
| 2018-06-30 | -$672.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | -$848.00K 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | -$176.00K 10-Q · filed 2019-05-14 | |||
| 2017-12-31 | $2.35M 10-K · filed 2019-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |